The new data comes from the KEYLYNK-001 study evaluating Keytruda (pembrolizumab) and chemotherapy followed by Lynparza (olaparib) maintenance therapy with or without bevacizumab in patients with ...
Evaluate notes that further data on the role of combined PD-1/PD-L1 and PARP inhibitor therapy as first-line maintenance therapy for advanced ovarian cancer will come from the Keylynk-001 study of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback